Research Directory

The stately progress of antibiotics

Read more

Global oncology has many first-in-class compounds

Read more

Cheap capital gives rise to integrated pharma R&D

Read more

Commentary: Thought disruption in R&D discovery

Read more

Market Analysis: The outlook for European pharma

Read more

New risk capital for European companies

Read more

A strategy for treating traumatic brain injury

Read more

Treating the immune system, not the tumour

Read more

Debate heats up over germline editing

Read more

Outlook brightens for European cell and gene therapy industry

Read more